Related Experiment Video
Updated: Jul 15, 2026

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
Published on: March 30, 2017
Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics
Anthony J Hickey1, Heidi M Mansour, Martin J Telko
1Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill, Campus Box #7360, 1310 Kerr Hall, Chapel Hill, North Carolina 27599-7360, USA. ahickey@unc.edu
Abstract:
Characteristics of particles included in dry powder inhalers is extended from our previous report (in this journal) to include properties related to their dynamic performance. The performance of dry powder aerosols for pulmonary delivery is known to depend on fluidization and dispersion which reflects particle interactions in static powder beds. Since the solid state, surface/interfacial chemistry and static bulk properties were assessed previously, it remains to describe dynamic performance with a view to interpreting the integrated database. These studies result in complex data matrices from which correlations between specific properties and performance may be deduced. Lactose particles were characterized in terms of their dynamic flow, powder and aerosol electrostatics, and aerodynamic performance with respect to albuterol aerosol dispersion. There were clear correlations between flow properties and aerosol dispersion that would allow selection of lactose particles for formulation. Moreover, these properties can be related to data reported earlier on the morphological and surface properties of the carrier lactose particles. The proposed series of analytical approaches to the evaluation of powders for inclusion in aerosol products has merit and may be the basis for screening and ultimately predicting particle performance with a view to formulation optimization.
Related Concept Videos
Inhaled Medications
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Factors Affecting Dissolution: Particle Size and Effective Surface Area

